6533b829fe1ef96bd12896dd

RESEARCH PRODUCT

Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.

Susana Rosello KeranenGuillem ArgilesRodrigo DienstmannAndrés CervantesNiels Jorgen Ostergaard SkartvedUlla H. HansenStephan BraunMarta Benavent ViñualesRocio Garcia CarboneroIvan D. Horak

subject

Cancer ResearchCetuximabColorectal cancermedicine.drug_classbusiness.industrymedicine.diseaseMonoclonal antibodymedicine.disease_causedigestive system diseasesOncologymedicineCancer researchPanitumumabIn patientKRASAnti-EGFR Monoclonal Antibodybusinessneoplasmsmedicine.drug

description

3551 Background: Preclinical models suggest that WT KRAS mCRC may retain EGFR dependency despite resistance developed to anti-EGFR mAb treatment (eg, cetuximab or panitumumab). Sym004 is the first-...

https://doi.org/10.1200/jco.2014.32.15_suppl.3551